Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial Article

cited authors

  • Chevli, K. Kent; Shore, Neal D.; Trainer, Andrew; Smith, Angela B.; Saltzstein, Daniel; Ehrlich, Yaron; Raman, Jay D.; Friedman, Boris; D'Anna, Richard; Morris, David; Hu, Brian; Tyson, Mark; Sankin, Alexander; Kates, Max; Linehan, Jennifer; Scherr, Douglas; Kester, Steven; Verni, Michael; Chamie, Karim; Karsh, Lawrence; Cinman, Arnold; Meads, Andrew; Lahiri, Soumi; Malinowski, Madlen; Gabai, Nimrod; Raju, Sunil; Schoenberg, Mark; Seltzer, Elyse; Huang, William C.

Publication Date

  • January 1, 2022

webpage

published in

category

keywords

  • clinical trial, phase II
  • mitomycin
  • urinary bladder neoplasms

start page

  • 61

end page

  • 68

volume

  • 207

issue

  • 1